Zum Inhalt

2000

 

 

 

 

Impact

Factor

Boulday, G., Coulon, F., de Martin, R., Soulillou, J.P., Charrreau, B. Identification and characterization of novel porcine molecules specifically regulated on endothelial cells by human complement activation.  Transplant Proc. 2000, Vol. 32(5), p977-978

0.590

Brostjan, C., Sobanov, Y., Glienke, J., Hayer, S., Lehrach, H., Francis, F. and Hofer, E. The NKG2 natural killer cell receptor family: comparative analysis of promoter sequences.  Genes & Immunity, 2000, 1, p504-508

 

0.000

Bull, C., Sobanov, Y., Röhrdanz, B., O´Brien, J., Lehrach, H. and Hofer, E. The centromeric part of the human NK gene complex: Linkage of LOX-1 and LY49L with the CD94 / NKG2 region.

Genes and Immunity, 2000, 1, p280-287

0.000

Carroll VA, Mihaly J, Koshelnick Y, Hufnagl P, Binder BR

Overexpression of plasminogen activator inhibitor type-1 in HT-1080 fibrosarcoma cells promotes lung colonization and in vitro cell adhesion.  Fibrinolysis and Proteolysis, 2000, Vol. 14(4), p215-220.

 

0.815

Daubenberger, C.A., Pöltl-Frank, F., Jiang, G., Lipp, J., Certa, U., and Pluschke, G. Identification and recombinant expression of glyceraldehyde-3-phosphate dehydrogenase of Plasmodium falciparum.  Gene, 2000, Vol. 246, p255-264

 

2.258

De Martin, R., Hoeth, M., Hofer-Warbinek, R. and Schmid, J.A The Transcription Factor NF-kB and the Regulation of Vascular Cell Function.  Arterioscler. Thromb. Vasc. Biol. 2000, Vol. 20, e83-e88

 

5.406

Griesenbach, U., Scheid, P., Hillery, E., de Martin, R., Huang, L., Geddes, DM and Alton, EW. Anti-inflammatory gene therapy directed at the airway epithelium.  Gene Ther. 2000, 7, p306-313

 

5.237

Hofer-Warbinek, R., Schmid, J.A., Stehlik, C., Binder, B.R., Lipp, J. and de Martin, R. Activation of NF-kB by XIAP, the X chromosome-linked inhibitor of apoptosis, in endothelial cells involves TAK1.  J Biol Chem. 2000, Volume 275 No. 29, Jul 21, p22064-22068

 

7.666

Korninger-Roller-RE; Janisch-S; Kvas-E; Schnedl-WJ; Binder-BR; Wojta-J; Korninger-C Smooth muscle cell migration promoting activity of plasma predicts restenosis in patients with peripheral arterial occlusive disease undergoing angioplasty.  Thrombosis and Haemostasis, 2000, Vol. 84(6) p1113-1116

 

4.983

Prendes MJ, Binder BR, Geiger M Protein C Inhibitor does exist in platelets  Blood, 2000, Vol. 95(5) p1881-1882

 

8.782

Schmid, J.A., Birbach, A., Hofer-Warbinek, R., Pengg, M., Burner, U., Furtmüller, P.G., Binder, B.R. and de Martin, R. Dynamics of NF-kB and IkBa studied with Green Fluorescent Protein (GFP) Fusion Proteins. Investigation of the GFP-p65 binding to DNA by fluorescence resonance energy transfer.  J Biol Chem. 2000, Vol. 275, No. 22, June 2, p17035-17042

 

7.666

Schwarz HP, Lenting PJ, Binder BR, Mihaly J, Denis C, Dorner F, Turecek PL Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice.  Blood, 2000, Vol. 95(5) p1703-1708

 

8.782

Sperr WR, Natter S, Baghestanian M, Smolen J, Wolff K, Binder BR, Muller MR, Lechner K, Valenta R, Valent P

Autoantibody reactivity in a case of Schnitzler´s syndrome: evidence for a Th1-like response and detection of IgG2 anti-FcepsilonRIalpha antibodies.  Int. Arch. Allergy Immunol. 2000, Vol. 122(4), p279-286.

 

1.911

Subbanagounder G, Leitinger N, Schwenke DC, Wong JW, Lee H, Rizza C, Watson AD, Faull KF, Fogelman AM, Berliner JA. Determinants of bioactivity of oxidized phospholipids: Specific oxidized fatty acyl groups at the sn-2 position.  Arterioscler Thromb Vasc Biol. 2000, Vol. 20, p2248-2254

 

5.406

Turecek PL, Schwarz HP, Binder BR

In vivo inhibition of low density lipoprotein receptor-related protein improves survival of factor VIII in the absence of von Willebrand factor.  Blood, 2000, Vol. 95(11), p3637-3678

 

8.782

Uhrin P, Dewerchin M, Hilpert M, Chrenek P, Schöfer C, Zechmeister-Machhart M, Krönke G, Vales A, Carmeliet P, Binder BR and Geiger M. Disruption of the protein C inhibitor gene results in impaired spermatogenesis and infertility.  J. Clin. Invest. 2000, Vol. 106, p1531-1539 (Editorial note p. 1429)

 

10.921

Gesamtimpact

79.205